CLDX Q2 2020 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$236,000-67.0% YoY

Gross Profit

-$9M-4012.3% margin

Operating Income

-$11M-4815.7% margin

Net Income

-$11M-4674.2% margin

EPS (Diluted)

$-0.50

QoQ Revenue Growth

-91.3%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$12M

Stock-Based Comp.

$721,000

Balance Sheet

Total Assets

$261M

Total Liabilities

$23M

Stockholders' Equity

$238M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$236,000	$715,000	-67.0%
Gross Profit	-$9M	-$9M	-1.1%
Operating Income	-$11M	-$12M	+7.3%
Net Income	-$11M	-$12M	+6.4%

Revenue Segments

Grant

$236,000100%